Volume 23, Number 10—October 2017
Poliovirus Excretion in Children with Primary Immunodeficiency Disorders, India
|Serial no.||Age, mo/ sex||PID type||Months from last OPV†||IVIG therapy||BMT||Results by collection day|
|1||114/F||IgG subclass deficiency||60||Yes||ND||D1, neg; D62, EV75; D214,neg; D250, neg; D419, neg; D476, neg; D685, neg|
|2||42/M||Hyper-IgE syndrome||24||No||ND||D1, E13; lost to follow-up|
|3||18/M||BENTA disease||NA||No||ND||D1, E5; D185, neg; D273, neg|
|4||30/M||CGD||NA||No||ND||D1, E14; D10, died|
|5||54/M||XLA||1||Yes||ND||D1, EV76; D107, neg; D136, neg; D260, neg|
*BENTA, B cell expansion with NF-κB and T cell anergy; BMT, bone marrow transplant; CGD, chronic granulomatous disease; D, day of collection following first collection; E5, echovirus 5; E13, echovirus 13; E14, echovirus 14; EV75, enterovirus 75; EV76, enterovirus 76; IVIG, intravenous immunoglobulin; NA, not available; ND, not done; neg, negative; OPV, oral polio vaccine; PID, primary immunodeficiency disease; XLA, X-linked agammaglobulinemia.
†Time from last OPV to first fecal sample collection.
- Page created: September 18, 2017
- Page last updated: September 18, 2017
- Page last reviewed: September 18, 2017
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)